| 1 |
Shiba N, et al. Chronic heart failure in Japan: implications
of the CHART studies. Vasc Health Risk Manag. 2008; 4: 103-13. PubMed |
| 2 |
Hori M, et al. Successful launch of cardiac transplantation
in Japan. Osaka University Cardiac Transplant Program. Jpn Circ J. 2000; 64:
326-32. PubMed |
| 3 |
Endoh M, et al. Acute heart failure: inotropic agents and
their clinical uses. Expert Opin Pharmacother. 2006; 7: 2179-202. PubMed |
| 4 |
Follath F, et al.; Steering Committee and Investigators of
the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety
of intravenous levosimendan compared with dobutamine in severe low-output heart
failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360:
196-202. PubMed |
| 5 |
Moiseyev VS, et al.; RUSSLAN Study Investigators. Safety and
efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular
failure due to an acute myocardial infarction. A randomized, placebo-controlled,
double-blind study (RUSSLAN). Eur Heart J. 2002; 23: 1422-32. PubMed |
| 6 |
Packer M, REVIVE II and SURVIVE: Use of Levosimendan for the
Treatment of Acute Decompensated Heart Failure. American Heart Association Annual
Meeting, Dallas, TX, USA. (13-16 Nov. 2005) |
| 7 |
Mebazaa A, et al.; SURVIVE Investigators. Levosimendan vs
dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized
Trial. JAMA. 2007; 297: 1883-91. PubMed |
| 8 |
Teerlink JR, et al. Relaxin for the treatment of patients
with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled,
parallel-group, dose-finding phase IIb study. Lancet. 2009; 373: 1429-39. PubMed |
| 9 |
Cotter G, et al.; Protect Steering Committee, Investigators,
and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled,
dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients
with acute heart failure and renal impairment. J Card Fail. 2008; 14: 631-40. PubMed |
| 10 |
Massie BM, et al.; PROTECT Investigators and Committees. Rolofylline,
an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;
363: 1419-28. PubMed |
| 11 |
Gheorghiade M, et al.; Efficacy of Vasopressin Antagonism
in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term
clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized
for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297: 1332-43. PubMed |
| 12 |
Konstam MA, et al.; Efficacy of Vasopressin Antagonism in
Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of
oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST
Outcome Trial. JAMA. 2007; 297: 1319-31. PubMed |
| 13 |
Flather MD, et al.; ACE-Inhibitor Myocardial Infarction Collaborative
Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular
dysfunction: a systematic overview of data from individual patients. Lancet.
2000; 355: 1575-81. PubMed |
| 14 |
Pitt B, et al.; Randomized Aldactone Evaluation Study Investigators.
The effect of spironolactone on morbidity and mortality in patients with severe
heart failure. N Engl J Med. 1999; 341: 709-17. PubMed |
| 15 |
Pitt B, et al.; Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective
aldosterone blocker, in patients with left ventricular dysfunction after myocardial
infarction. N Engl J Med. 2003; 348: 1309-21. PubMed |
| 16 |
Zannad F, et al.; EMPHASIS-HF Study Group. Eplerenone in patients
with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21. PubMed |
| 17 |
Packer M, et al.; ATLAS Study Group. Comparative effects of
low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril,
on morbidity and mortality in chronic heart failure. Circulation. 1999; 100:
2312-8. PubMed |
| 18 |
Konstam MA, et al.; HEAAL Investigators. Effects of high-dose
versus low-dose losartan on clinical outcomes in patients with heart failure
(HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374: 1840-8. PubMed |
| 19 |
Mann DL, et al. Targeted anticytokine therapy in patients
with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation
(RENEWAL). Circulation. 2004; 109: 1594-602. PubMed |
| 20 |
Torre-Amione G, et al.; Advanced Chronic Heart Failure CLinical
Assessment of Immune Modulation Therapy Investigators. Results of a non-specific
immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled
randomised trial. Lancet. 2008; 371: 228-36. PubMed |
| 21 |
Kjekshus J, et al.; CORONA Group. Rosuvastatin in older patients
with systolic heart failure. N Engl J Med. 2007; 357: 2248-61. PubMed |
| 22 |
Tavazzi L, et al.; Gissi-HF Investigators. Effect of rosuvastatin
in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial. Lancet. 2008; 372: 1231-9. PubMed |
| 23 |
McAlister FA, et al. Meta-analysis: beta-blocker dose, heart
rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;
150: 784-94. PubMed |
| 24 |
Fox K, et al.; BEAUTIFUL Investigators. Ivabradine for patients
with stable coronary artery disease and left-ventricular systolic dysfunction
(BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;
372: 807-16. PubMed |
| 25 |
Swedberg K, et al.; SHIFT Investigators. Ivabradine and outcomes
in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet.
2010; 376: 875-85. PubMed |
| 26 |
Anker SD, et al.; FAIR-HF Trial Investigators. Ferric carboxymaltose
in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361:
2436-48. PubMed |
| 27 |
Owan TE, et al. Trends in prevalence and outcome of heart
failure with preserved ejection fraction. N Engl J Med. 2006; 355: 251-9. PubMed |
| 28 |
Cleland JG, et al.; PEP-CHF Investigators. The perindopril
in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;
27: 2338-45. PubMed |
| 29 |
Yusuf S, et al.; CHARM Investigators and Committees. Effects
of candesartan in patients with chronic heart failure and preserved left-ventricular
ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777-81. PubMed |
| 30 |
Massie BM, et al.; I-PRESERVE Investigators. Irbesartan in
patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;
359: 2456-67. PubMed |
| 31 |
Flather MD, et al.; SENIORS Investigators. Randomized trial
to determine the effect of nebivolol on mortality and cardiovascular hospital
admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;
26: 215-25. PubMed |
| 32 |
Hori M, et al.; J-DHF Program Committee. Rationale and design
of a randomized trial to assess the effects of beta-blocker in diastolic heart
failure; Japanese Diastolic Heart Failure Study (J-DHF). J Card Fail. 2005; 11:
542-7. PubMed |
| 33 |
Cleland JG, et al.; Cardiac Resynchronization-Heart Failure
(CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity
and mortality in heart failure. N Engl J Med. 2005; 352: 1539-49. PubMed |
| 34 |
Bristow MR, et al.; Comparison of Medical Therapy, Pacing,
and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced chronic heart
failure. N Engl J Med. 2004; 350: 2140-50. PubMed |
| 35 |
Tang AS, et al.; Resynchronization-Defibrillation for Ambulatory
Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate
heart failure. N Engl J Med. 2010; 363: 2385-95. PubMed |
| 36 |
Moss AJ, et al.; MADIT-CRT Trial Investigators. Cardiac-resynchronization
therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361:
1329-38. PubMed |
| 37 |
Linde C, et al.; REVERSE (REsynchronization reVErses Remodeling
in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac
resynchronization in mildly symptomatic heart failure patients and in asymptomatic
patients with left ventricular dysfunction and previous heart failure symptoms.
J Am Coll Cardiol. 2008; 52: 1834-43. PubMed |
| 38 |
Beshai JF, et al.; RethinQ Study Investigators. Cardiac-resynchronization
therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007; 357:
2461-71. PubMed |
| 39 |
Chung ES, et al. Results of the Predictors of Response to
CRT (PROSPECT) trial. Circulation. 2008; 117: 2608-16. PubMed |
| 40 |
Rose EA, et al.; Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term
use of a left ventricular assist device for end-stage heart failure. N Engl J
Med. 2001; 345: 1435-43. PubMed |
| 41 |
Slaughter MS, et al.; HeartMate II Investigators. Advanced
heart failure treated with continuous-flow left ventricular assist device. N
Engl J Med. 2009; 361: 2241-51. PubMed |
| 42 |
O'Connor CM, et al.; HF-ACTION Investigators. Efficacy and
safety of exercise training in patients with chronic heart failure: HF-ACTION
randomized controlled trial. JAMA. 2009; 301: 1439-50. PubMed |
| 43 |
Jourdain P, et al. Plasma brain natriuretic peptide-guided
therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.
J Am Coll Cardiol. 2007; 49: 1733-9. PubMed |
| 44 |
Pfisterer M, et al.; TIME-CHF Investigators. BNP-guided vs
symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical
Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized
trial. JAMA. 2009; 301: 383-92. PubMed |
